Weedstocks Newswire Feed
VANCOUVER, Oct. 15, 2018 /CNW/ - EPHS Holdings Inc., (the "Company" or "EPHS") (OTCQB: STNN), together with Joint Venture Partner, Merritt Valley Cannabis, today announced its intention to commence work on its expansion plan located in Merritt, British Columbia, Canada. The 56-acre Merritt site is located on industrial properties, has 40MW of low-cost energy immediately available with all required services in place and is zoned for both cannabis and technology infrastructure. With expansion plans already on the horizon, a phased campus roll-out will provide EPHS with the ability to scale the facility to 1.2 million square feet over time.
EPHS intends to break ground in early 2019 on the company's cannabis campus. Phase one will span 30,000 square feet of production and extraction facilities and is scheduled for opening in early 2020.
"Our expansion plans and methodologies for Merritt Valley are based on industry experience and learned understandings. Our vision, which revolves around simplicity and focus, combines high yield cultivation methods and intellectual property with industry leading low-cost energy rates." commented Stevan Perry, chief executive officer of Merritt Valley Cannabis.
EPHS Holdings, Inc. chief executive officer, Gianfranco Bentivoglio stated, "What excites us is the economic development benefits that the Merritt Valley Cannabis project will bring to the City of Merritt. Recent studies have shown that a one million square foot cannabis facility can produce up to 500 direct and indirect jobs and an estimated one billion dollars of economic benefits for the region.".
About EPHS Holdings Inc.
TerrAscend Secures Multi-Year Cannabis Supply Agreement with PharmHouse Inc., a Canopy Rivers Joint Venture
TORONTO, Oct. 15, 2018 /CNW/ - TerrAscend Corp. (CSE: TER) ("TerrAscend" or the "Company"), today announced that its subsidiary TerrAscend Canada Inc. (o/a Solace Health) ("TerrAscend Canada") has entered into a multi-year cultivation agreement with PharmHouse Inc. ("PharmHouse"), a joint venture between Canopy Rivers Inc. (TSXV: RIV) ("Canopy Rivers") and the principals and operators of a leading North American greenhouse produce company.
Under the terms of the agreement, PharmHouse will grow and supply cannabis to TerrAscend Canada from an existing 1.3 million square foot greenhouse ("Facility"), located in Leamington, Ontario. Once fully licensed, the production of flower, trim and clones from 20% of the dedicated flowering space at the Facility will be made available to TerrAscend Canada.
TerrAscend Canada may provide proprietary genetic strains to PharmHouse and help oversee production in conjunction with their operators and quality assurance professionals. Cultivation is anticipated to commence in 2019, subject to receipt by PharmHouse of all applicable regulatory licenses and approvals.
Michael Nashat, President and Chief Executive Officer, stated, "This agreement provides TerrAscend with access to high quality greenhouse grown cannabis and significantly advances our strategy in focusing on the production of premium products and standardized dosage forms, consistent with GMP standards. Partnering with PharmHouse further offers TerrAscend large-scale cultivation expertise and production capabilities."
About TerrAscend Corp. TerrAscend Corp. is a biopharmaceutical and wellness company that is committed to quality products, brands and services for the global cannabinoid market. On October 9, 2018, TerrAscend announced its intentions to expand into the US market. The Company provides support to patients and consumers through its wholly-owned subsidiaries, TerrAscend Canada Inc., o/a Solace Health, a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations, Solace Health Network Inc., a clinical support program and education platform led by healthcare professionals and Solace Health, the online marketplace for the licensed producer. The Company will also participate in the adult-use market in Canada following legalization through direct and indirect supply agreements in several provinces. The Company holds a partnership with leading researchers in Ascendant Labs, a cannabis biotechnology and licensing company committed to the continuous improvement of the cannabis plant.
MISSISSAUGA, ON, Oct. 15, 2018 /CNW/ - Career Compass Canada, an HR advisory firm, is reminding employers to update their Employee Handbooks to reflect the new Cannabis Act, legalizing Marijuana, that is enacted into law this coming Wednesday.
"Employers need to take action now, if they have not yet done so, to update their policies related to this new legislation. Basically, the cannabis policy should mirror a company's policy on the use of Alcohol at a minimum," said Alexander Lutchin, company President. "Some organizations may go further in demanding additional time between the use of cannabis and reporting for work. Both employers and employees need to use common sense and act responsibly," he said.
Communication and training is also vital in rolling out the policy. "Employees need to know what their policy is and what the company expectations are", said Melissa Jones, Vice President, Client Services and Talent Strategies. "There cannot be any gaps between company policy and employees knowing what that policy is. We encourage all companies to ensure that they are acknowledging the new Act, and updating their policies accordingly."
Companies who fail to develop a written policy are exposing themselves to unnecessary risk that needs to be mitigated to ensure a safe and respectful workplace. This is a work in progress as Employers adapt to this new reality and being mindful and alert will go a long way to managing potential issues.
About Career Compass Canada
Wayland Signs Minimum 9,000 kilograms Supply Agreement with Cannamedical for Export of Product from Canada to Germany
TORONTO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Wayland Group (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland” or the “Company) is pleased to announce that it has entered into an agreement to supply Cannamedical Pharma GmbH, a licensed, privately owned importer and distributor of cannabis in Germany to over 2,200 pharmacies with a minimum of 9,000 kilograms of EU-GMP certified cannabis flowers over a three year term. The companies have completed mandatory quality assurance and control audits and have scheduled the first shipment in December of 2018.
“The decision we made in early 2017 to move to EU-GMP standards for all production, including cannabis flowers, followed by certification in the spring of this year by the German Health Authorities, provides the Company with the opportunity to move a significant amount of product, in this case 9,000 kilograms to Germany. We’re proud to be one of six companies worldwide out of thousands of cannabis producers who can say we pass the test and exceed EU-GMP standards for dry cannabis flowers. This agreement will provide meaningful revenue and profit to the Company over the next three years as we build a sustainable business,” stated Ben Ward, CEO of Wayland.
“We are pleased to enter into this agreement with Wayland. Being able to meet the exponentially growing demand of our European client base strengthens our position as the largest independent and privately-owned cannabis distributor in Germany. Cannamedical will formally introduce its CannaSativa®, CannaIndica® and Cannahybrid® product lines during next week’s German pain congress in Mannheim, Germany,” stated David Henn, CEO of Cannamedical.
Maricann Group Inc., through its subsidiaries, is operating under the Wayland Group name. For further details see the press release dated September 24, 2018.
About Wayland Group
KELOWNA, BC, Oct. 15, 2018 /CNW/ - Valens GroWorks Corp. (CSE: VGW) (the "Company" or "Valens"), a multi-licensed, vertically integrated provider of cannabis products and services utilizing proprietary extraction processes is pleased to announce that Health Canada has granted the Company their license to cultivate and produce oil under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR"). The receipt of this license marks the third cannabis license granted to the Company by Health Canada.
The Company received the license to cultivate and produce oil as a Licensed Producer ("LP") under the ACMPR through it's wholly-owned subsidiary, Valens Agritech Ltd. ("VAL"). The Company's 25,000 square foot facility in Kelowna BC, built specifically for extraction, is now licensed under both the Narcotics Control Regulations ("NCR") and the ACMPR, allowing the Company to transition into Canada's emerging adult use market with a regulatory advantage.
"With the two regulatory bodies merging on October 17th, the receipt of our LP license is a step we deemed necessary to ensure the Company has every opportunity to capitalize on the adult-use, medical and retail cannabis space, both domestically and internationally. Our license to cultivate and produce oil under the ACMPR brings us one step closer to being able to offer Valens-branded products directly to consumers here in Canada. We are excited to finally share this milestone which plays vitally into our business development plans." says Valens GroWorks Corp. CEO, Tyler Robson.
The Company's latest efforts have focused on expansion opportunities into international markets and working on obtaining EU GMP certification. The receipt of the LP license under the ACMPR, combined with the closing of the $27.3 million bought deal financing and the Company's recent procurement of the exclusive Canadian rights to the production and distribution of Tarukino Holdings Inc.'s proprietary emulsion technology SōRSE™, demonstrates Valens' ability to strategically position itself to capitalize on every market available, both globally and domestically.
Research published today shows significant decline in driving-related ability even after five hours
MONTREAL, Oct. 15, 2018 /CNW/ - Young Canadians are more at risk of a vehicle crash even five hours after inhaling cannabis, according to results of a clinical trial conducted at the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University, and funded by the Canadian Automobile Association (CAA).
The research found that performance declined significantly, in key areas such as reaction time, even five hours after inhaling the equivalent of less than one typical joint. The participants' driving performance, which was tested in a driving simulator, deteriorated as soon as they were exposed to the kinds of distractions common on the road.
The peer-reviewed study is published online today at 6:00 a.m. EST at CMAJ Open, an online sister journal to CMAJ (Canadian Medical Association Journal).
The trial examined the impact of cannabis on the driving ability of 18 to 24 year old occasional users. CAA polling has found that a significant number of young Canadians – one in five - believe they are as good or better drivers stoned as they are sober.
FSD Pharma and SciCann Therapeutics to Attend the CannX International Medical Cannabis Convention in Tel Aviv Israel
CSE: HUGE OTCQB: FSDDF FRA: 0K9
TORONTO, Oct. 14, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma") (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce that its Head of Scientific Advisory Board, Dr. Zohar Koren, will attend the 3rd International Medical Cannabis Conference, ("CannX") in Tel Aviv, Israel from October 14 to 16, 2018.
The CannX convention is a central annual meeting point of global leaders in all areas related to medical cannabis and cannabinoid medicine. The convention will feature the latest scientific developments in this rapidly evolving field, including cultivation, extraction and manufacturing cutting-edge technologies and clinical research breakthroughs. The convention will also showcase Key Opinion Leaders that are physicians and researchers including Professor Rafael Mechoulam, the Israeli scientist who was the first to discover the human endocannabinoid system.
FSD Pharma and its strategic R&D partner, SciCann Therapeutics Inc. ("SciCann Therapeutics"), are actively seeking novel technologies that may synergize with their own advanced cannabinoid scientific research programs. Dr. Zohar Koren, Head of the Scientific Advisory Board for FSD Pharma and CEO of SciCann Therapeutics, will lead these efforts and will meet leading Israeli scientists, clinicians, and biotech firms that wish to collaborate with the two companies.
Zeeshan Saeed, EVP and Director of FSD Pharma, stated "We are excited about the attendance of FSD Pharma at the international CannX conference through our Head of the Scientific Advisory Board, Dr. Zohar Koren. Our deep collaboration with SciCann Therapeutics allows us a first line look into the heart of the thriving Cannabis R&D medical research arena of Israel, where most advancements in cannabinoid science have been made in the last few decades. We look forward to meeting the leading cannabis researchers and clinicians working diligently in Israel, and expect to review multiple collaboration opportunities through our attendance at CannX."
TORONTO, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Wayland Group (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland” or the “Company”) wishes to make the following statements regarding recent market activity in its common shares traded on the OTCQB marketplace.
The Company has been asked to issue this release by OTC Markets to comment on certain continued promotional activities beginning on or around October 1, 2018. The Company became aware of certain continued promotional activity relating to its securities on October 8, 2018 upon receipt of correspondence from OTC Markets specifically related to certain promotional literature encouraging investors to purchase the Company's common shares and making certain statements regarding the potential returns on such investment, including certain promotional newsletter emails. Until being informed by OTC Markets of the promotional material, the Company was unaware of the promotional activity and remains unaware of the full nature of the promotional activity and the extent of the dissemination. It is difficult to determine what impact the promotional materials have had on the trading activity in the Company's common shares but the Company believes that, if anything, such materials have had a negative impact on the trading activity of the Company's common shares given the lower than average volumes experienced recently on the OTCQB marketplace.
Upon reviewing the content of the material, it appears that certain statements and claims made were taken from the Company’s website, historical press releases and other public documents, but the Company had no editorial control over the content of the material. Furthermore, there are statements made which encourage investors to purchase the common shares of the Company, which only express the view of the authors and the Company disclaims any potentially exaggerated or misleading statements contained in the material. In addition, the Company has determined that certain statements included in these publications related to the Company and its business might be read as misleading and/or incomplete and readers should not place undue reliance on these newsletters or websites. Specifically, the Company does not condone the use of sensational language to describe the Company’s business prospects or the growth potential of the Company’s industry. The Company does not condone any statements made regarding the urgency of investing in the Company’s common shares or any other similar statements. Finally, the Company notes that investing in the Company’s securities involves certain risks and uncertainties that investors should review prior to making any investment decision. The Company encourages all investors to undertake proper due diligence and carefully consider all investment decisions. The Company directs potential investors to rely solely on its filings and disclosures made with Canadian securities regulators, available at www.sedar.com and as posted on the filings and disclosure page for MRRCF on the OTC Markets website at www.otcmarkets.com.
The Company routinely responds to inquiries from shareholders, potential investors, and investment analysts, and generates its own Company marketing materials. The Company paid a media service, Tycona Media, to place banner advertisements on high traffic websites for the cannabis industry, complete with images of one employee and the Company’s historic greenhouse operations. These media slots were purchased and booked one month in advance. However, to the Company's knowledge, after due inquiry of management, neither the Company, nor any of its officers, directors, controlling shareholders or any third-party service providers have directly been involved with the creation or distribution of promotional newsletter emails or websites that make exaggerated or misleading claims related to the Company and its securities. In addition, the Company confirms that, after due inquiry, none of its officers, directors, controlling shareholders or third party service providers has had any affiliation or arrangements with Lake Group Media Inc. The Company notes Invictus News has included a statement in certain of its material regarding an agreement to pay Invictus News for its services but it appears that this statement was taken directly from the disclaimer used by Tycona Media. The Company confirmed with Tycona Media that Tycona Media has not paid Invictus News or other promoters to disseminate information about the Company. The Company confirms that it does not have any engagement or agreement with Invictus News, Invictus MD – The Cannabis Company, Gene Simmons and or TSX-V: GENE.
After due inquiry of the Company's officers, directors, controlling shareholders and third party service providers, except for two officers that engaged in a securities lending arrangement (see press release dated August 10, 2018), neither the Company, nor any of its officers, directors, and to the knowledge of the Company, any controlling shareholders or third party service providers have sold or purchased the Company's securities within the past 90 days. Such transactions were in accordance with the Company's insider trading policy and were reported with the System for Electronic Disclosure (www.SEDI.ca).
Terra Tech Corp. Announces Plans to Expand its Cannabis Dispensary Footprint with Purchase of Las Vegas Property
IRVINE, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Terra Tech Corp. (OTCQX: TRTC), (“Terra Tech” or the “Company”) a vertically integrated cannabis-focused agriculture company, today announced it has purchased a retail property in downtown Las Vegas, located at 121 North Fourth Street. The Company plans to convert the building into a Blüm™ retail dispensary, focused on providing the highest quality medical and adult use cannabis to the Nevada market.
The 4,541+ square feet retail building rests on a single 0.16 acre land parcel on North 4th Street, just 100 feet from the world famous Fremont Street Experience, which attracts more than 14 million annual visitors. Positioned in the heart of the booming Downtown Las Vegas trade area, the property has always provided very solid ground for its retail tenants.
Terra Tech currently operates three other Blüm stores in Nevada, two of which are in Las Vegas, and all of which are focused on providing the highest level of personal care coupled with a broad selection of medical and adult use cannabis products, including flowers, concentrates and edibles. Its proprietary Blüm retail brand first entered Nevada in April 2016, and now enjoys significant brand recognition among its loyal customer base. Capitalizing on the Blüm brand by expanding into Downtown Las Vegas will expand the Company’s Nevada footprint and is expected to bolster its reputation as a leading retail dispensary operator in one of the U.S.’s largest cannabis markets. The Company has submitted two retail permit applications to the State and plans to announce the result of these applications as soon as possible.
Derek Peterson, CEO of Terra Tech, stated, “We remain committed to growing our footprint in Nevada, which remains a lucrative market for the cannabis sector. The building is located in the heart of the booming Downtown Las Vegas trade area, an area in which we did not previously have a presence but which benefits from high foot traffic. Last year, 32 percent of the visitors to Las Vegas visited the downtown area. Of those, 59 percent said the main reason was to visit the Fremont Street Experience. We are pleased to have secured this building, which has great street-front visibility, and expect that, once it has been rebranded and fully-licensed under our recognizable Blüm brand, it will contribute meaningfully to the Company’s revenue growth.”
To be added to the Terra Tech email distribution list, please email TRTC@kcsa.com with TRTC in the subject line.
TORONTO, Oct. 12, 2018 /CNW/ - The Green Organic Dutchman Holdings Ltd. (the "Company" or "TGOD") (TSX:TGOD) (US:TGODF) announces that the first milestone option (the "Milestone Option") under the Investor Rights Agreement (the "Agreement") between TGOD and Aurora Cannabis Inc. ("Aurora") (TSX:ACB) has expired. The Milestone Option entitled Aurora to acquire an additional 8% of the common shares of the Company.
The milestone was achieved on August 2nd, 2018, three months after the Company's shares became listed on the TSX. The Milestone Option provided Aurora with the right to purchase 8% of the Company's shares (on a fully diluted basis) from treasury for cash at a 10% discount to the 10-day VWAP. Under the Agreement, the Milestone Option has now expired, and the Company has elected not to provide a further extension. In addition, pursuant to the terms of the Agreement, all remaining Milestone Options to acquire additional interests in the Company have expired.
Aurora continues to maintain the right to purchase up to 20% of TGOD's premium organic cannabis from the Company's two facilities under construction in Canada. The selling price is based on a revenue sharing arrangement, similar to wholesale pricing.
"Aurora has been an incredible partner to date and both parties plan to continue the partnership. They invested $78.1 million into our Company and added tremendous value across multiple areas of collaboration, including the design and construction of our Canadian facilities," said Brian Athaide, CEO of TGOD. "Our recent $75 million bought deal financing ensures TGOD has the capital necessary to continue our international expansion at a rapid pace, extending sales and distribution to more channels throughout Europe and Latin America. While the Milestone Option has expired, many possibilities exist in the future for our two very complementary companies," continued Athaide.
On Behalf of the Board of Directors, The Green Organic Dutchman Holdings Ltd.